



NOTICE OF CHANGE OF AUDITOR

TO: Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Manitoba Securities Commission
Saskatchewan Securities Commission
New Brunswick Securities Commission
Newfoundland & Labrador Securities Commission
Nova Scotia Securities Commission
Prince Edward Island Securities Commission

AND: the CSE Exchange

AND: Clearhouse LLP, Chartered Professional Accountants

AND: DNTW LLP, Chartered Professional Accountants

Pursuant to National Instruction 51-102, Revive Therapeutics Ltd. (the "Company") hereby advises that:

1. On September 10, 2024, the Company received the resignation of Clearhouse LLP, Chartered Professional Accountants;
2. On September 10, 2024, the Company appointed DNTW LLP, Chartered Professional Accountants, to fill the vacancy created by the resignation of Clearhouse LLP, and to hold such position until the close of the next annual meeting of shareholders of the Company. The resignation of Clearhouse LLP and the appointment of DNTW LLP was considered and approved by the Board of Directors of the Company.
3. There were no modifications of opinion by Clearhouse LLP in the Auditors' Reports of the two most recently completed fiscal years ended December 31, 2022 and December 31, 2023.
4. The Board of Directors of the Company is of the opinion that there were no "reportable events" as defined by National Instrument 51-102, which occurred in connection with the audit of the two most recently completed fiscal years or for any period subsequent to the most recently completed fiscal period for which an Auditors' Report was issued.

We confirm that the Board of Directors has reviewed and approved this Notice of Change of Auditor.

ON BEHALF OF THE BOARD OF DIRECTORS

Dated this 10th day of September 2024

By: /s/ Carmelo Marrelli
Carmelo Marrelli, Chief Financial Officer